Drug metabolism in human liver microsomes assessed as 2-(3,4-Dimethoxybenzyl)-5-methyl-7-((2S,3S)-2,4,6-trihydroxy-6-phenylhexan-3-yl)imidazo[5,1-f ][1,2,4]triazin-4(3H)-one formation at 20 uM after 1 hr by UHPLC-UV-HRMS method
Drug metabolism in human liver microsomes assessed as 7-((2S,3S)-2,6-Dihydroxy-6-phenylhexan-3-yl)-2-(3-hydroxy-4-methoxybenzyl)-5-methylimidazo[5,1-f ][1,2,4]triazin-4(3H)-one formation at 20 uM after 1 hr by UHPLC-UV-HRMS method
Drug metabolism in human liver microsomes assessed as 7-((2S,3R)-2,6-Dihydroxy-6-phenylhexan-3-yl)-2-(3,4-dimethoxybenzyl)-5-methylimidazo[5,1-f][1,2,4]triazin-4(3H)-one diastereomer 1 formation at 20 uM after 1 hr by UHPLC-UV-HRMS method
Drug metabolism in human liver microsomes assessed as 7-((2S,3R)-2,6-Dihydroxy-6-phenylhexan-3-yl)-2-(3,4-dimethoxybenzyl)-5-methylimidazo[5,1-f][1,2,4]triazin-4(3H)-one diastereomer 2 formation at 20 uM after 1 hr by UHPLC-UV-HRMS method
Drug metabolism in human liver microsomes assessed as 2-(3,4-Dimethoxybenzyl)-7-((2S,3S)-2-hydroxy-6-oxo-6-phenylhexan-3-yl)-5-methylimidazo[5,1-f ][1,2,4]triazin-4(3H)-one formation at 20 uM after 1 hr by UHPLC-UV-HRMS method